LATEST ALERTS
Health and science
The common sense of CBD science, and why it doesn’t always come to the fore
21st April 2022 - Blogs , News analysis |
Is the current system of peer-reviewed journal publication the best way to get the best science on CBD and cannabis? There could be another way
US medical cannabis products: a state-by-state regulatory report
20th April 2022 - Regulatory reports |
This regulatory report analyses the different approaches taken by states over what restrictions they impose on medical cannabis products that patients can buy
So far so good, but German lawmakers urged to go further on medical cannabis
11th April 2022 - News analysis |
Five years after German patients were first allowed to obtain medical cannabis, demand has risen sharply – but there are still some unanswered issues on policy and practice that lobbyists want addressed
Medical cannabis company receives government grant…
8th April 2022 - Alerts | Australasia, New Zealand |
Long trips for a short supply, but there’s optimism in Iowa on medical cannabis
6th April 2022 - News analysis |
Patients in Iowa who rely on supplies of medical cannabis are tightly restricted in how much they can have, and may face a long trip to get it from one of the few licensed dispensaries in the US state
Cannabis a key element in future health planning…
4th April 2022 - Alerts | Argentina, South America |
Hospitals added to authorised cannabis importers…
4th April 2022 - Alerts | Brazil, South America |
Canada’s proposed changes could open up non-therapeutic cannabis research
31st March 2022 - News analysis |
The Canadian government is proposing changes to make it easier to conduct non-therapeutic cannabis research in the country and to foster more investigation into the development of cannabis products
FDA sends CBD companies warning letters over Covid health claims….
31st March 2022 - Alerts | North America, United States |
Could the Pfizer acquisition of Arena be a sign of things to come in Big Pharma?
4th March 2022 - News analysis |
While Big Pharma acquisitions of companies involved in the development of cannabinoid treatments are expected to to propel and expand cannabinoid treatment options, the overall impact of and interest in Big Pharma’s reach into the industry remains a matter of speculation
More medical applications for cannabinoids being explored
4th March 2022 - News analysis |
Scientists around the world are starting to look even further afield for potential uses of cannabis in medical applications, such as treating the symptoms of long Covid-19, Alzheimer’s-related agitation, and to alleviate the pain resulting from HIV
22nd Century Group to make further advances into cannabinoid production
3rd March 2022 - News analysis |
US firm 22nd Century Group plans to use its expertise in plant science, biotechnology and genetics to move further into cannabinoid production
South American legislation on cannabis and hemp will progress, if slowly, in 2022
8th February 2022 - News analysis |
This is an important year for positive legislation affecting cannabinoids across South America, though some depends on election results and all of it will take a few years to take effect
Costa Rica’s president promises to get cannabis legalisation done despite veto
7th February 2022 - News analysis |
Costa Rican president Carlos Alvarado, who has supported the legalisation of cannabis throughout his administration, has partially vetoed a bill that would have legalised medicinal cannabis and industrial hemp
Early research shows some cannabinoids can prevent Covid-19 infecting cells
3rd February 2022 - News analysis |
Research from scientists at the University of Oregon suggests that certain cannabinoids can stop the SARS-CoV-2 (Covid-19) virus from infecting cells. This may lead to future treatments
US lawsuits end DEA restrictions on sources of cannabis for researchers
26th January 2022 - News analysis |
Lawsuits in the US have finally overturned the DEA’s requirement that researchers interested in studying cannabis could only purchase from one source, the University of Mississippi
CBD’s popularity sparks gold rush to develop rare cannabinoids
19th January 2022 - News analysis |
Potential demand for rarer cannabinoids is prompting firms to explore other methods of manufacturing, such as biosynthesis and chemical synthesis, to give higher yields at lower cost
Insurance rule ‘a billion-dollar shot in the arm’ for Colombian cannabis market
11th January 2022 - News analysis |
Colombian insurance providers must now cover the cost of medical cannabis prescriptions, a move that could represent a “billion-dollar shift” in the market – and perhaps lay down a marker for other countries
Colombian insurance policy shows real intent to lead on cannabinoids
6th January 2022 - Blogs , News analysis |
Colombia has joined a select few countries now demanding mandatory coverage of medical cannabis by health insurance providers
Picking the right variety – what seeds are permitted and which grows best where?
31st December 2021 - News analysis |
Desired end product and environmental factors are the two things best kept in mind when considering hemp varieties for different countries
Guidelines on real world data could bring cannabinoid drugs to UK patients sooner
30th December 2021 - News analysis |
New guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) on the use of real word data and evidence to support clinical trials could help cannabinoid products gain approval
‘Snake oil’ claims for CBD and Covid-19 top latest list of US FDA warning letters
29th December 2021 - News analysis |
The most common subject of recent warning letters from the US Food and Drug Administration (FDA) over unsubstantiated health claims was CBD products that were claimed to mitigate, prevent, treat, diagnose or cure Covid-19
CBD-Intel’s crystal ball reveals possible intoxicating prospects for the year ahead
29th December 2021 - News analysis |
“Intoxicating” will be the word to watch for and THC will be the main driver for developments in 2022, CBD-Intel predicts
So it’s farewell to 2021 – a year that promised little and delivered less
27th December 2021 - News analysis |
If 2020 was the year in the waiting-room then 2021 was perhaps the year of the unfulfilled hype. As predicted, there was little movement in many of the major issues controlling the CBD market
Intoxicating hemp products in the US – opportunity or risk?
20th December 2021 - Regulatory reports |
Some sellers of intoxicating cannabinoid products claim legality under the 2018 US Farm Bill. CBD-Intel believes that many hemp-derived cannabinoids do not violate federal controlled substance law
UK health trust teams up with Awakn to investigate psychedelic treatment
13th December 2021 - News analysis |
The UK’s National Health Service (NHS) has expressed some interest in the viability of psychedelics as a course of treatment
Podcast: A UK doctor’s take on CBD
25th November 2021 - Podcasts |
CBD-Intel podcast editor Jon Bruford meets Dr K CBD’s Dr Ruchira Karunadasa who explains why he believes the company has an important role to play in helping the industry towards mature dialogue, and the impact that
Gupta’s appointment and nomination of Califf may indicate change in US climate
16th November 2021 - News analysis |
Rahul Gupta has been confirmed by the US Senate as director of National Drug Control Policy, while president Joe Biden intends to nominate Robert Califf as head of the US Food and Drug Administration (FDA)
Two studies seek to show the benefits of cannabinoids for liver health
5th November 2021 - News analysis |
A research team at the University Medical Center Groningen (UMCG) in the Netherlands recently launched a three-year study into whether medicinal cannabis oil can help to regress liver-cancer tumours
Concerns arise as Italian study finds pesticides and metals in hemp flowers
29th October 2021 - News analysis |
Another study, this time from Italy, has found potentially dangerous levels of heavy metals and pesticides in CBD products. Researchers were worried by the results and asked regulators and legislators to act
Brazilian report highlights theoretical growth but small current numbers
22nd October 2021 - News analysis |
Interest in the Brazilian medical cannabinoid market is based on optimistic projections of growth continuing in the same vein rather than concrete current numbers, a domestic report has confirmed
Potential for psychedelic treatments prompts big North American buyouts
15th October 2021 - News analysis |
Interest in psychedelic drugs and treatments continues to grow, as evidenced by three major takeovers in Canada and the USA, two involving drug treatments developments and another offering a network of ketamine infusion treatment centres
Charlotte’s Web new dietary ingredient application did include ValidCare data
14th October 2021 - Blogs , News analysis |
It turns out the Charlotte’s Web application to the US FDA for the registration of a full spectrum hemp extract as a new dietary ingredient (NDI) DID include data from the ValidCare industry study
Personal mental health histories lead to investments in psychedelics research
12th October 2021 - News analysis |
Two North American entrepreneurs have put millions of dollars into exploring the treatment efficacy of psychedelics, based on personal experience of using them to help deal with their own mental health issues
German medical cannabis imports rise but no sign of domestic production yet
8th October 2021 - News analysis |
German imports of medical cannabis flowers rose by 80% in the first half of 2021 compared to the same period of 2021, but hopes of establishing local production were dashed
US DEA calls for big increases in cannabis and psilocybin production for research
23rd September 2021 - News analysis |
The US Drug Enforcement Agency (DEA) is calling for an increase in production of cannabis and psychedelics to supply federal research and clinical trials
NFL vet claims orange-peel CBD ‘purer’ than cannabis or hemp-derived products
13th September 2021 - News analysis |
NFL veteran Chris Hetherington has launched a CBD oil derived entirely from orange peel, describing it as “crystalline CBD at a purity and consistency difficult to match with cannabis or hemp-derived material”
Horse sense or dog trial? The science and law behind CBD petcare products
1st September 2021 - News analysis |
CBD pet products remain in a grey area in terms of both legality and effectiveness – but there have been some attempts in both to shed light into the darkness
The entourage effect: new studies could help to explain the phenomenon
18th August 2021 - News analysis |
Two new studies on the biochemistry of cannabinoids could provide answers to a puzzling question – how does the entourage effect work?
Medical use of psilocibyn in Canada could grow, but consumer sale unlikely
13th August 2021 - News analysis |
A court case could force the Canadian government to process requests to use psilocybin for psychotherapeutic treatment more quickly
Testing the testers: UK and US CBD testing labs go under the microscope
13th August 2021 - News analysis |
A recent ring trial assessment of the lab performances and methods for measuring CBD in commercial products has given some good news to the industry
What lies behind the CBD industry’s continued interest in the field of nicotine replacement?
11th August 2021 - Blogs , News analysis |
A new study has shown some limited effectiveness for the use of CBD in combatting nicotine withdrawal symptoms
Test-tube cannabinoids: scientists seek alternatives to agricultural production
11th August 2021 - News analysis |
New methods for laboratory production of cannabinoids show some promise – but it’s still not clear whether they will yield enough to be commercially viable
Study raises early hopes for the use of CBD in treating nicotine withdrawal
5th August 2021 - News analysis |
Researchers at the University of San Diego in California have published a paper showing early evidence that CBD may help ease the symptoms of nicotine withdrawal
